aducanumab

aducanumab
IUPAC name	Immunoglobulin G1, anti-(human amyloid beta), human-mouse chimeric monoclonal antibody (heavy chain (1-449)) disulfide with human-mouse chimeric monoclonal antibody light chain (1-219), dimer
CAS number	1384260-65-4
DrugBank	DB15699
ATC prefix	N07
ATC suffix	XX01
ChemSpiderID	none
UNII	105J35OE21
Synonyms	BIIB037

aducanumab is a monoclonal antibody therapy designed for the treatment of Alzheimer's disease. It was developed by Biogen in collaboration with Neurimmune and targets aggregated forms of amyloid beta protein in the brain. The drug received accelerated approval from the U.S. Food and Drug Administration in 2021, a decision that generated significant debate within the medical and scientific communities. Its development and regulatory pathway have been closely scrutinized by organizations like the World Health Organization and various national health agencies.

History and development

The foundational research for aducanumab originated from the University of Zurich, where scientists from Neurimmune identified the antibody from the immune cells of elderly individuals who showed resistance to cognitive decline. Biogen later licensed the compound, initiating a major drug development program aimed at modifying the course of Alzheimer's disease. Key preclinical studies were conducted at institutions like Massachusetts General Hospital and presented at conferences such as the Alzheimer's Association International Conference. The collaboration expanded to include Eisai, a Japanese pharmaceutical company, for co-development and commercialization efforts in certain regions. The project's progression was closely monitored by regulatory bodies including the European Medicines Agency and the Pharmaceuticals and Medical Devices Agency in Japan.

Mechanism of action

Aducanumab is an immunoglobulin G1 monoclonal antibody engineered to bind specifically to aggregated forms of amyloid beta, including soluble oligomers and insoluble fibrils. This binding is believed to facilitate the clearance of these protein aggregates from the brain via microglia, the resident immune cells of the central nervous system. The therapeutic hypothesis is rooted in the amyloid hypothesis, which posits that the accumulation of amyloid beta plaques is a primary driver of the neurodegeneration seen in Alzheimer's disease. By targeting these pathological hallmarks, the drug aims to slow the progression of clinical decline, a theory supported by data from positron emission tomography imaging studies conducted at centers like the Mayo Clinic and Stanford University.

Clinical trials and efficacy

The clinical development program for aducanumab consisted of several pivotal studies, including the Phase 1b PRIME study and the larger Phase 3 trials known as EMERGE and ENGAGE. These multinational trials enrolled patients with early Alzheimer's disease and used endpoints such as the Clinical Dementia Rating scale and the Mini-Mental State Examination. While the EMERGE trial met its primary endpoint, showing a statistically significant reduction in clinical decline, the ENGAGE trial did not. A subsequent pooled analysis and data re-examination by Biogen led to the controversial conclusion of clinical benefit. These results were hotly debated at advisory committee meetings for the U.S. Food and Drug Administration and in journals like The New England Journal of Medicine and The Lancet.

Regulatory approval and controversy

In June 2021, the U.S. Food and Drug Administration granted aducanumab accelerated approval under its accelerated approval program, a pathway typically reserved for serious conditions with unmet need. This decision was made despite the Peripheral and Central Nervous System Drugs Advisory Committee voting overwhelmingly against recommending approval, citing insufficient evidence of efficacy. The controversy prompted investigations by the House Committee on Oversight and Reform and critical editorials in publications like JAMA and The BMJ. Following the U.S. decision, regulatory agencies such as the European Medicines Agency and Health Canada declined to approve the drug, while the Therapeutic Goods Administration in Australia also rejected the application.

Administration and dosage

Aducanumab is administered as a monthly intravenous infusion, typically in a clinical setting such as a hospital infusion center or specialized memory clinic. The dosing regimen involves a titration phase to reach a maintenance dose, as recommended in the prescribing information from the U.S. Food and Drug Administration. Administration requires premedication with agents like methylprednisolone to mitigate the risk of amyloid-related imaging abnormalities. The logistics of treatment, including the need for regular magnetic resonance imaging monitoring, were established through protocols developed during the clinical trials conducted at sites like the Cleveland Clinic and Johns Hopkins Hospital.

Adverse effects and safety

The most significant safety concern associated with aducanumab is amyloid-related imaging abnormalities, which manifest as brain edema or microhemorrhages detectable on magnetic resonance imaging. Other reported adverse events include headache, falls, and diarrhea, as documented in clinical trial data submitted to the U.S. Food and Drug Administration. The risk profile led the agency to mandate a post-marketing study, a requirement under the accelerated approval program. Ongoing safety surveillance is managed by Biogen and monitored by independent bodies like the Data and Safety Monitoring Board. These safety considerations have been a focal point for organizations such as the American Academy of Neurology and the Alzheimer's Association in their treatment guidelines.

Category:Monoclonal antibodies Category:Alzheimer's disease Category:Biogen